# Liver Cirrhosis Treatment Market > Liver Cirrhosis Treatment Market Research Report Information By Treatment (Antibiotics, Immunosuppressants) and End-User (Hospitals and Clinics, Research and Academic Institutes) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 6.93% - **2024:** $ 14.12 Billion - **2025:** $ 15.1 Billion - **2035:** $ 29.51 Billion - **Key Players:** Gilead Sciences (US), AbbVie (US), Bristol-Myers Squibb (US), Merck & Co. (US), Novartis (CH), Roche (CH), Amgen (US), Eisai (JP), Hepion Pharmaceuticals (US) **Report ID:** MRFR/HC/6895-HCR · **Pages:** 111 · **Author:** Vikita Thakur & Kinjoll Dey · **Last Updated:** May 15, 2026 **URL:** https://www.marketresearchfuture.com/reports/liver-cirrhosis-treatment-market-8367 --- ## Market Summary ## **Liver Cirrhosis Treatment Market Forecast** **Liver Cirrhosis Treatment Market Size** was valued at USD 13.23 Billion in 2023. The **Global Liver Cirrhosis Treatment Industry** is projected to grow from USD 14.12 Billion in 2024 to USD 24.13 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.92% during the forecast period (2024 - 2032). ### **Liver Cirrhosis Treatment Market Synopsis** Liver cirrhosis is a disease in which the liver is severely damaged and scarred, hence leading to liver failure. A lot of research activities are being carried out by major pharmaceutical companies to develop novel drugs for the treatment of liver cirrhosis. Rapidly changing lifestyle is increasing the risk of people suffering from liver cirrhosis. Moreover, people suffering from hepatitis, cystic fibrosis, syphilis, [alpha-1 antitrypsin deficiency](../../../reports/alpha-1-antitrypsin-deficiency-treatment-market-8319), alcohol abuse, and other liver diseases are at greater risk of suffering from liver cirrhosis. As of 2015, 887,000 deaths people died suffering from hepatitis B. Most of these deaths were because these patients were suffering from liver cirrhosis and hepatocellular carcinoma (primary liver cancer) along with hepatitis B. ### **Market Influencer** The increasing prevalence of liver cirrhosis expected to contribute to the growth of the liver cirrhosis treatment market in the near future. ### **Market Drivers** - Increasing prevalence of liver cirrhosis. As of January 2019, liver cirrhosis accounted for 3.5% of all the deaths worldwide. - Rapidly changing lifestyle - Growing awareness programs regarding liver diseases - Rising R&D investment for the development of innovative drugs for liver diseases - High geriatric population. Between the years 2015 and 2050, the percentage of geriatric population is expected to double from 12% to 22%. - Increasing demand for better treatment methods for curing liver cirrhosis ### **Market Restraints** - Stringent government regulations - High investment required for drug research and development - Side-effects of medications prescribed for liver cirrhosis ## **Liver Cirrhosis Treatment Market Segmentation** ### **By Treatment** **Antibiotics** The largest segment of the liver cirrhosis treatment market. Antibiotics are prescribed for infections associated with liver cirrhosis. As of February 2016, 30% to 50% of deaths of cirrhosis patients occurred because of bacterial infections. **Immunosuppressants** The fastest-growing segment. Immunosuppressants are prescribed to reduce the body’s ability to reject the transplanted liver. Approximately, 8,082 liver transplants were performed in 2016. **Others** This segment includes medications prescribed for the treatment of underlying causes of liver cirrhosis such as Hepatitis B or C. Moreover, antihypertensive drugs, drugs for the reduction of ammonia, medications for reduction of blood pressure, and nutritional supplements are also covered in this segment. ### **By End-User** **Hospitals and Clinics** The largest segment. Hospitals and clinics are the primary points of care for the treatment of liver cirrhosis. Rising prevalence of liver cirrhosis is expected to drive the liver cirrhosis treatment market growth. **Research and Academic Institutes** These centers carry out research activities for the innovation of novel drugs for the treatment of liver cirrhosis. **Others** This segment includes centers for home care and elderly population. ### **By Region** **Americas** The largest regional market. The prevalence of liver cirrhosis is high in the Americas. Approximately, 88,000 people died suffering from alcohol-related liver disease and liver cirrhosis in the US as of October 2017. Moreover, the healthcare infrastructure in the Americas is also developed, which contributes to liver cirrhosis treatment market growth. Furthermore, major pharmaceutical companies such as **Pfizer Inc.** and **Gilead Sciences, Inc.** are headquartered in the US which positively contributes to the growth of the liver cirrhosis treatment market in the Americas. **Europe** An increasing geriatric population and rising R&D investment for the development of innovative drugs for liver diseases is anticipated to drive the market growth in Europe. Finland and the UK are known to observe increasing level of liver disease mortality since the last 40 years. European countries such as the UK, Germany, and France among others, have a well-developed healthcare infrastructure, which contributes to the growth of the liver cirrhosis treatment market in Europe. **Asia-Pacific** The fastest-growing regional market. Asia-Pacific is seeing a surge in the number of people suffering from liver cirrhosis. Moreover, government and non-government organizations are conducting awareness programs for liver cirrhosis which is expected to drive the liver cirrhosis treatment market growth. Furthermore, the geriatric population is prone to various liver diseases, and it is increasing in countries such as India, Japan, and China, which is positively affecting liver cirrhosis treatment market growth. It is estimated that, by the year 2050, one in four people in Asia and the Pacific region would be aged 60 years or more. **Middle East & Africa** The liver cirrhosis treatment market is expected to show significant growth due to the rising patient population suffering from liver cirrhosis. The liver cirrhosis treatment market in the Middle East is expected to show more growth as compared to the African market owing to fast-developing healthcare facilities in the Middle Eastern countries such as Saudi Arabia, Qatar, and Oman. ## **Liver Cirrhosis Treatment Market Key Players** - Pfizer, Inc. (US) - [Merck](https://www.msdmanuals.com/professional/hepatic-and-biliary-disorders/fibrosis-and-cirrhosis/cirrhosis) & Co., Inc. (Germany) - Novartis AG (Switzerland) - Hoffmann-La Roche Ltd (Switzerland) - Takeda Pharmaceutical Company Limited (Japan) - Gilead Sciences, Inc. (US) - AstraZeneca (UK) - Bayer AG (Germany) - Sanofi (France) - Shionogi Inc. (Japan) - Promethera (Belgium) ## Market Drivers ### Increasing Healthcare Expenditure The rise in healthcare expenditure across various regions is a crucial driver for the Liver Cirrhosis Treatment Market. As countries allocate more resources to healthcare, there is a corresponding increase in funding for liver disease research and treatment. This trend is particularly evident in developed nations, where healthcare budgets are expanding to accommodate advanced treatment options and technologies. For example, the healthcare expenditure in the United States is projected to exceed USD 4 trillion by 2025, with a significant portion directed towards [chronic disease management](https://www.marketresearchfuture.com/reports/chronic-disease-management-market-981), including liver cirrhosis. This financial commitment is likely to enhance access to innovative therapies and improve patient outcomes, thereby stimulating market growth. Additionally, increased public awareness and advocacy for liver health may further drive healthcare investments in this area. ### Rising Prevalence of Liver Diseases The increasing incidence of liver diseases, particularly hepatitis and alcoholic liver disease, is a primary driver of the Liver Cirrhosis Treatment Market. According to recent data, liver cirrhosis affects millions worldwide, with estimates suggesting that approximately 1.5 million deaths occur annually due to liver-related conditions. This alarming trend necessitates the development and availability of effective treatment options, thereby propelling market growth. As healthcare systems strive to address this growing burden, investments in research and development of innovative therapies are likely to increase. Furthermore, the rising awareness of liver health and the importance of early diagnosis may lead to more patients seeking treatment, further expanding the market for liver cirrhosis therapies. ### Growing Awareness and Education Initiatives The growing awareness and education initiatives surrounding liver health are pivotal in shaping the Liver Cirrhosis Treatment Market. Campaigns aimed at educating the public about the risks associated with liver diseases, including lifestyle factors and the importance of regular screenings, are gaining traction. Organizations and healthcare providers are increasingly focusing on outreach programs to inform individuals about liver cirrhosis and its treatment options. This heightened awareness is likely to lead to earlier diagnosis and treatment, which can significantly improve patient outcomes. Furthermore, as more individuals become informed about liver health, the demand for effective treatment solutions is expected to rise, thereby propelling the market forward. The emphasis on preventive care and education may also encourage healthcare systems to invest more in liver disease management. ### Regulatory Support for Innovative Therapies Regulatory support for innovative therapies is emerging as a vital driver in the Liver Cirrhosis Treatment Market. Regulatory agencies are increasingly recognizing the need for expedited approval processes for new treatments, particularly those addressing unmet medical needs in liver disease management. Initiatives such as breakthrough therapy designations and fast-track approvals are facilitating the entry of novel therapies into the market. This supportive regulatory environment is likely to encourage pharmaceutical companies to invest in research and development of new treatment options for liver cirrhosis. As a result, the market may witness a surge in the availability of effective therapies, which could significantly enhance patient care. Moreover, the collaboration between regulatory bodies and industry stakeholders may foster innovation, ultimately benefiting patients suffering from liver cirrhosis. ### Technological Advancements in Treatment Modalities Technological innovations in treatment modalities are significantly influencing the Liver Cirrhosis Treatment Market. The emergence of novel pharmacological agents, such as direct-acting antivirals and antifibrotic drugs, has transformed the therapeutic landscape for liver cirrhosis. These advancements not only enhance treatment efficacy but also improve patient compliance and outcomes. For instance, the introduction of minimally invasive surgical techniques and advanced imaging technologies has facilitated better management of complications associated with cirrhosis. Market data indicates that The Liver Cirrhosis Treatment Market is projected to reach USD 20 billion by 2026, driven by these technological advancements. As research continues to evolve, the potential for new treatment options remains high, suggesting a robust future for the liver cirrhosis treatment sector. ## Future Outlook The Liver Cirrhosis Treatment Market is projected to grow at a 6.93% CAGR from 2025 to 2035, driven by increasing prevalence, advancements in therapies, and rising healthcare expenditure. **New opportunities:** - Development of personalized medicine approaches for targeted therapies. - Expansion of telehealth services for [remote patient monitoring](https://www.marketresearchfuture.com/reports/remote-patient-monitoring-market-10905). - Investment in AI-driven diagnostic tools for early detection. By 2035, the market is expected to achieve substantial growth, reflecting evolving treatment paradigms and increased patient access. ## Segment Insights ### By Treatment: Antibiotics (Largest) vs. Immunosuppressants (Fastest-Growing) In the Liver Cirrhosis Treatment Market, the treatment segment is predominantly led by Antibiotics, which holds the largest market share. This class of medications is essential for combating infections in patients suffering from liver cirrhosis and is commonly prescribed in clinical settings. Immunosuppressants, while currently a smaller segment, have shown rapidly increasing adoption due to the rising number of cases requiring liver transplantation and autoimmune management associated with cirrhosis. As healthcare awareness grows, the need for these treatments increases, impacting market dynamics significantly. Antibiotics (Dominant) vs. Immunosuppressants (Emerging) Antibiotics represent the dominant treatment option in the Liver Cirrhosis Treatment Market, primarily due to their critical role in managing bacterial infections that frequently complicate liver disease. They tend to be the first line of defense for patients, particularly those facing issues like spontaneous bacterial peritonitis. On the other hand, Immunosuppressants are emerging as an important alternative therapy, especially in patients with autoimmune liver diseases. Their rapid growth is driven by advancements in clinical practices and a better understanding of the underlying mechanisms of liver cirrhosis, which expands their role in treatment protocols. ### By End-User: Hospitals and Clinics (Largest) vs. Research and Academic Institutes (Fastest-Growing) The Liver Cirrhosis Treatment Market shows a significant distribution among three primary end users: hospitals and clinics, research and academic institutes, and others. Hospitals and clinics lead the market due to their extensive patient base and comprehensive treatment services, accounting for the largest share. In contrast, research and academic institutes are rapidly gaining traction, reflecting the increasing focus on innovative treatments and advancements in liver cirrhosis care. Their contribution is pivotal in enhancing treatment protocols and overall patient outcomes. The growth trends in the Liver Cirrhosis Treatment Market are largely driven by an increase in cirrhosis prevalence and a heightened demand for effective treatment solutions. Hospitals and clinics are prioritizing cutting-edge therapies and patient-centric approaches, influencing their dominant market position. Alternatively, research and academic institutes experience growth fueled by collaborations with pharmaceutical companies and their role in clinical trials, aiming to bring forth new therapies that address unmet medical needs in liver care. This dynamic landscape underscores the importance of both sectors in progressing liver cirrhosis treatment methodologies. Hospitals and Clinics (Dominant) vs. Research and Academic Institutes (Emerging) Hospitals and clinics serve as the backbone of the Liver Cirrhosis Treatment Market, providing a wide spectrum of services and advanced treatment options. Their presence not only ensures immediate care but also plays a crucial role in patient management and recovery. They are typically equipped with state-of-the-art technology and expert healthcare professionals, enabling them to handle complex liver disease cases effectively. In contrast, research and academic institutes represent the emerging segment, focusing on innovative solutions and groundbreaking research. Their pivotal role in studying disease mechanisms and developing novel therapies positions them as vital contributors to the future of liver treatment. By fostering academic-industry partnerships, these institutions are accelerating the arrival of transformative therapies to the market, making them an essential part of the overall ecosystem. ## Regional Market Share Analysis ### North America : Leading Innovation and Research North America is the largest market for liver cirrhosis treatment, accounting for approximately 45% of the global market share. The region benefits from advanced healthcare infrastructure, high prevalence of liver diseases, and significant investments in research and development. Regulatory support from agencies like the FDA further catalyzes market growth, ensuring rapid approval of innovative therapies and treatments. The United States is the primary contributor, with key players such as Gilead Sciences, AbbVie, and Bristol-Myers Squibb leading the competitive landscape. The presence of these major pharmaceutical companies, along with ongoing clinical trials and collaborations, enhances the market's potential. Canada also plays a significant role, focusing on improving treatment accessibility and patient outcomes, thereby strengthening the overall market position. ### Europe : Emerging Regulatory Frameworks Europe is the second-largest market for liver cirrhosis treatment, holding around 30% of the global market share. The region is witnessing a surge in demand due to increasing liver disease prevalence and supportive regulatory frameworks. Initiatives by the European Medicines Agency (EMA) to streamline drug approvals are expected to enhance market growth, making innovative treatments more accessible to patients. Leading countries include Germany, France, and the UK, where healthcare systems are increasingly prioritizing liver health. Major players like Novartis and Roche are actively involved in developing new therapies. The competitive landscape is characterized by collaborations between pharmaceutical companies and research institutions, aiming to improve treatment efficacy and patient care. The focus on personalized medicine is also gaining traction, further driving market dynamics. ### Asia-Pacific : Rapidly Growing Market Potential Asia-Pacific is an emerging powerhouse in the liver cirrhosis treatment market, contributing approximately 20% to the global market share. The region's growth is driven by rising liver disease prevalence, particularly in countries like China and India, where lifestyle changes and increasing alcohol consumption are significant factors. Government initiatives aimed at improving healthcare access and affordability are also propelling market expansion. China and Japan are the leading countries in this region, with a growing number of pharmaceutical companies entering the market. Key players such as Eisai and Hepion Pharmaceuticals are focusing on innovative treatment solutions. The competitive landscape is evolving, with local companies increasingly collaborating with The Liver Cirrhosis Treatment reach, thereby improving treatment options for patients suffering from liver cirrhosis. ### Middle East and Africa : Untapped Market Opportunities The Middle East and Africa region represents a smaller segment of the liver cirrhosis treatment market, holding about 5% of the global share. However, it is characterized by significant growth potential due to increasing awareness of liver diseases and the need for effective treatment options. The region's healthcare systems are gradually improving, with governments focusing on enhancing healthcare infrastructure and access to treatments. Countries like South Africa and the UAE are leading the way in adopting new therapies, with a growing presence of international pharmaceutical companies. The competitive landscape is marked by partnerships between local and global firms, aiming to address the rising demand for liver cirrhosis treatments. As healthcare initiatives expand, the market is expected to witness substantial growth in the coming years, driven by both public and private sector investments. ## Competitive Benchmarking The Liver Cirrhosis Treatment Market is characterized by a dynamic competitive landscape, driven by increasing prevalence rates and a growing demand for effective therapies. Key players such as Gilead Sciences (US), AbbVie (US), and Bristol-Myers Squibb (US) are at the forefront, each adopting distinct strategies to enhance their market presence. Gilead Sciences (US) focuses on innovation, particularly in antiviral therapies, while AbbVie (US) emphasizes strategic partnerships to bolster its research capabilities. Bristol-Myers Squibb (US) is actively pursuing mergers and acquisitions to expand its portfolio, indicating a trend towards consolidation in the market. Collectively, these strategies contribute to a competitive environment that is increasingly centered on innovation and collaboration. In terms of business tactics, companies are localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. The market structure appears moderately fragmented, with several players vying for market share. However, the influence of major companies is substantial, as they leverage their resources to shape market dynamics and drive advancements in treatment options. In August 2025, Gilead Sciences (US) announced a collaboration with a leading biotechnology firm to develop a novel therapeutic approach for liver cirrhosis, which underscores its commitment to innovation. This partnership is likely to enhance Gilead's research capabilities and accelerate the development of new treatments, positioning the company favorably in a competitive market. In September 2025, AbbVie (US) launched a new clinical trial aimed at evaluating the efficacy of its latest drug candidate for liver cirrhosis. This initiative not only reflects AbbVie's focus on expanding its therapeutic offerings but also highlights its proactive approach to addressing unmet medical needs. The outcomes of this trial could significantly influence AbbVie's market positioning and future growth. In July 2025, Bristol-Myers Squibb (US) completed the acquisition of a smaller pharmaceutical company specializing in liver disease treatments. This strategic move is indicative of the company's intent to diversify its portfolio and enhance its capabilities in the liver cirrhosis segment. The acquisition is expected to provide Bristol-Myers Squibb with access to innovative therapies and a broader patient base, thereby strengthening its competitive edge. As of October 2025, current trends in the Liver Cirrhosis Treatment Market include a pronounced shift towards digitalization and the integration of artificial intelligence in drug development processes. Strategic alliances are increasingly shaping the landscape, enabling companies to pool resources and expertise. Looking ahead, competitive differentiation is likely to evolve, with a greater emphasis on innovation and technology rather than solely on price. Companies that can effectively navigate these trends and enhance supply chain reliability will likely emerge as leaders in this evolving market. ## Report Scope | MARKET SIZE 2024 | 14.12(USD Billion) | | --- | --- | | MARKET SIZE 2025 | 15.1(USD Billion) | | MARKET SIZE 2035 | 29.51(USD Billion) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.93% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Billion | | Key Companies Profiled | Gilead Sciences (US), AbbVie (US), Bristol-Myers Squibb (US), Merck & Co. (US), Novartis (CH), Roche (CH), Amgen (US), Eisai (JP), Hepion Pharmaceuticals (US) | | Segments Covered | Treatment | | Key Market Opportunities | Advancements in personalized medicine enhance treatment efficacy in the Liver Cirrhosis Treatment Market. | | Key Market Dynamics | Rising demand for innovative therapies drives competition and regulatory scrutiny in the Liver Cirrhosis Treatment Market. | | Countries Covered | North America, Europe, APAC, South America, MEA | ## Frequently Asked Questions **Q: What is the projected market valuation for the Liver Cirrhosis Treatment Market in 2035?** A: The projected market valuation for the Liver Cirrhosis Treatment Market in 2035 is 29.51 USD Billion. **Q: What was the market valuation for the Liver Cirrhosis Treatment Market in 2024?** A: The market valuation for the Liver Cirrhosis Treatment Market in 2024 was 14.12 USD Billion. **Q: What is the expected CAGR for the Liver Cirrhosis Treatment Market from 2025 to 2035?** A: The expected CAGR for the Liver Cirrhosis Treatment Market during the forecast period 2025 - 2035 is 6.93%. **Q: Which companies are considered key players in the Liver Cirrhosis Treatment Market?** A: Key players in the Liver Cirrhosis Treatment Market include Gilead Sciences, AbbVie, Bristol-Myers Squibb, Merck & Co., Novartis, Roche, Amgen, Eisai, and Hepion Pharmaceuticals. **Q: What are the projected revenues for antibiotics in the Liver Cirrhosis Treatment Market by 2035?** A: The projected revenues for antibiotics in the Liver Cirrhosis Treatment Market are expected to reach between 6.0 USD Billion by 2035. **Q: How much revenue is anticipated from immunosuppressants in the Liver Cirrhosis Treatment Market by 2035?** A: Immunosuppressants are anticipated to generate revenues between 8.0 USD Billion by 2035. **Q: What is the expected revenue from hospitals and clinics in the Liver Cirrhosis Treatment Market by 2035?** A: The expected revenue from hospitals and clinics in the Liver Cirrhosis Treatment Market is projected to be 17.5 USD Billion by 2035. **Q: What revenue growth is expected from research and academic institutes in the Liver Cirrhosis Treatment Market by 2035?** A: Revenue from research and academic institutes in the Liver Cirrhosis Treatment Market is expected to grow to 6.8 USD Billion by 2035. **Q: What is the projected revenue for 'Others' segment in the Liver Cirrhosis Treatment Market by 2035?** A: The projected revenue for the 'Others' segment in the Liver Cirrhosis Treatment Market is expected to reach 15.51 USD Billion by 2035. **Q: How does the Liver Cirrhosis Treatment Market's growth compare across different segments?** A: The Liver Cirrhosis Treatment Market shows varied growth across segments, with antibiotics, immunosuppressants, and hospital revenues all indicating substantial increases by 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/liver-cirrhosis-treatment-market-8367*